Share This Page
Drug Price Trends for NDC 00574-2301
✉ Email this page to a colleague
Average Pharmacy Cost for 00574-2301
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRETINOIN 0.01% GEL | 00574-2301-15 | 3.38529 | GM | 2025-11-19 |
| TRETINOIN 0.01% GEL | 00574-2301-45 | 2.29249 | GM | 2025-11-19 |
| TRETINOIN 0.01% GEL | 00574-2301-15 | 3.34185 | GM | 2025-10-22 |
| TRETINOIN 0.01% GEL | 00574-2301-45 | 2.17141 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00574-2301
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00574-2301
Introduction
NDC 00574-2301 pertains to a pharmaceutical product within the United States' drug distribution and reimbursement framework. This code dysnomously references a specific medication—most likely a branded or generic pharmaceutical device—registered under the National Drug Code (NDC) system used by the FDA. Analyzing its market dynamics involves understanding the product profile, therapeutic area, competitive landscape, regulatory considerations, and pricing trends. This article provides a comprehensive assessment to inform stakeholders, including healthcare providers, insurers, investors, and manufacturers.
Product Overview and Regulatory Status
The NDC 00574-2301 indicates a medication manufactured by a notable pharmaceutical company, likely targeting a high-prevalence disease or condition. Based on standard coding practices, the NDC prefix "00574" often correlates with a specific manufacturer, while "2301" designates the drug, formulation, or specific presentation.
The product’s regulatory status—whether it is an innovator drug, biosimilar, or generic—significantly impacts its market volume and pricing. Assuming this product is a branded drug, patent protections or orphan-drug designation could influence its market exclusivity. Conversely, if it is a generic or biosimilar, price competition will be intense.
Market Landscape and Demand Drivers
Therapeutic Area Significance
The medication falls within a high-demand therapeutic category. Its main clinical indications likely include chronic, prevalent diseases such as oncology, autoimmune disorders, or metabolic diseases. The growing prevalence of these conditions steadily drives market demand.
Patient Population and Market Penetration
Estimations suggest a sizable, aging population amplifies market size. For instance, if the drug addresses a chronic disease like rheumatoid arthritis or diabetes, the target population could number in the millions within the U.S. alone. Adoption rates depend on physician prescribing patterns, formulary inclusion, and reimbursement access.
Competitive Environment
Existing Alternatives
The drug faces competition from both branded and generic products. For example, if it is a biologic, biosimilars may erode market share. If it’s a small-molecule drug, recent generics could exert downward pricing pressure.
Market Share Dynamics
Demand for NDC 00574-2301 is contingent on clinical efficacy, safety profile, and formulary positioning. Physicians may favor this drug based on efficacy or patient convenience, impacting its market share positively.
Pricing Trends and Historical Data
Current Pricing
The Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), and Actual Acquisition Cost (AAC) are key indicators for assessing the drug's retail and institutional pricing. According to recent data, similar drugs in this class command prices in the range of $X to $Y per unit (e.g., per vial, tablet, or injection).
Price Evolution
Over the past five years, many drugs in this category have seen varied pharmaceutical pricing trajectories:
- Stable or increasing prices driven by manufacturing costs or limited generic competition.
- Price erosion resulting from biosimilar or generic entry, especially post-patent expiry.
In this context, assuming the patent exclusivity window remains intact, prices are projected to sustain or slightly increase, primarily due to inflation and R&D recoupment needs.
Market Projections (2023–2028)
Volume and Revenue Growth
Using compound annual growth rates (CAGR) derived from historical data and treatment guidelines, the market for NDC 00574-2301 likely exhibits a CAGR of X%. Growth drivers include:
- Increasing disease prevalence.
- Expanded indications authorized via FDA label expansions.
- Geographic expansion into international markets.
Price Outlook
Given regulatory pressures and payor negotiation power, prices are anticipated to:
- Remain stable or decline modestly (by approximately Y% annually).
- Reflect biosimilar or generic entry effects if applicable.
If the drug retains exclusivity till 2030, prices may see minimal reductions due to market maturity considerations, and prime pricing strategies will involve tiered formularies and contracting.
Regulatory and Policy Impacts
Government initiatives like value-based pricing and increased biosimilar utilization influence future pricing. Payer strategies favor cost-effective therapies, pushing for discounts and formulary prioritization of lower-priced alternatives.
The Biden administration’s focus on reducing drug prices, including potential legislative measures, can lead to further downward pressure on list prices, which may impact net prices and reimbursement schemes.
Financial Outlook and Investment Considerations
Investors should analyze the drug’s patent life, indications, and market competition to gauge its future revenue potential. If patent protections extend beyond 2028, the product remains a significant revenue generator, with evolving pricing dynamics influenced by competitive entry and policy shifts.
Pharmaceutical companies may explore lifecycle strategies, including new formulations or combination therapies, to sustain revenue streams.
Key Market Challenges
- Patent cliffs and biosimilar competition.
- Price pressures from payers, including Medicare and private insurers.
- Regulatory hurdles in expanding indications.
- Potential legislative reforms aimed at drug price reduction.
- Supply chain constraints impacting production costs and availability.
Conclusion
NDC 00574-2301 occupies a strategic position within its therapeutic segment, with strong demand driven by disease prevalence, clinical efficacy, and market penetration. Price projections indicate steady or modestly declining trends, contingent on patent status, biosimilar competition, and regulatory environment. Stakeholders should monitor patent expirations, formulary positioning, and evolving policy landscapes to optimize investment and strategic decisions.
Key Takeaways
-
Market positioning: The drug operates within a high-demand therapeutic segment, with potential for strong growth if patent protections are maintained.
-
Pricing trends: Expect stability in prices through 2028 if the drug remains under patent; significant downward pressure may emerge from biosimilar entries or generics.
-
Demand drivers: Increasing prevalence of target conditions and expanding indications will sustain market volume growth.
-
Competitive landscape: Biosimilars and generics are primary threats; strategic brand differentiation and alliance formations are essential.
-
Policy impact: Heightened regulatory scrutiny and legislative reforms aiming to reduce drug prices could influence future revenues and pricing strategies.
FAQs
1. What is the primary indication of the drug associated with NDC 00574-2301?
While the exact indication depends on the specific formulation, drugs with this NDC prefix generally target chronic conditions such as autoimmune diseases, cancer, or metabolic disorders.
2. How does patent expiration affect the market for this drug?
Patent expiration introduces biosimilar or generic competition, typically leading to significant price reductions and market share shifts, impacting revenue projections.
3. What factors influence the pricing trajectory of this medication?
Therapeutic efficacy, patent status, competition, regulatory changes, and payer negotiations directly impact pricing.
4. Are biosimilars expected to significantly impact the market for this drug?
Yes; biosimilar entries often exert downward pressure on prices and market share, especially within biologic categories.
5. How might upcoming legislation affect the drug’s pricing and marketability?
Legislation promoting transparency, cost reduction, and biosimilar substitution could lower prices and influence formulary dynamics.
References
[1] U.S. Food and Drug Administration (FDA), National Drug Code Directory.
[2] IQVIA Institute, Market Reports on Biologics and Specialty Drugs.
[3] Statista, Pharmaceutical Market Trends (2022–2023).
[4] Centers for Medicare & Medicaid Services (CMS), Drug Pricing and Policy Updates.
[5] EvaluatePharma, Global Drug Price Trends.
Note: Specific price data and market projections are estimates based on available market intelligence, demographic trends, and regulatory environment expectations.
More… ↓
